

Filippo de Marinis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2930643/publications.pdf>

Version: 2024-02-01

120
papers

8,839
citations

136740

32
h-index

45213

90
g-index

121
all docs

121
docs citations

121
times ranked

10105
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet</i> , The, 2017, 389, 255-265.	6.3	3,872
2	First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2018-2029.	13.9	592
3	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1468-1479.	5.1	370
4	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1233-1243.	0.5	324
5	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 2866-2873.	0.8	316
6	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. <i>European Radiology</i> , 2016, 26, 32-42.	2.3	210
7	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1156-1170.	0.5	195
8	Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 101-114.	1.4	178
9	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 713-721.	5.1	157
10	Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7312-7319.	3.2	139
11	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 764-773.	0.5	128
12	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019, 128, 105-112.	0.9	126
13	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 35-40.	0.9	122
14	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. <i>ESMO Open</i> , 2020, 5, e000820.	2.0	96
15	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naïve Programmed Death-Ligand 1-Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	0.5	85
16	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018, 100, 126-134.	1.3	83
17	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	0.5	77
18	Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration. <i>American Journal of Clinical Pathology</i> , 2015, 144, 629-634.	0.4	65

#	ARTICLE	IF	CITATIONS
19	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3951.	1.8	62
20	Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014, 15, 173-181.	1.1	56
21	Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. <i>Pharmacological Research</i> , 2017, 117, 406-415.	3.1	55
22	Salvage Surgery After Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2017, 29, 233-241.	0.4	51
23	Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PivOTAL observational study. <i>PLoS ONE</i> , 2018, 13, e0202865.	1.1	50
24	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017, 6, 373-386.	1.3	45
25	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2021, 22, 1438-1447.	5.1	45
26	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. <i>Journal of Clinical Oncology</i> , 2018, 36, 9043-9043.	0.8	45
27	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	3.2	44
28	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014.	1.1	42
29	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , 2020, 89, 102085.	3.4	41
30	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019, 20, e186-e194.	1.1	40
31	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 461-465.	1.1	37
32	A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. <i>European Journal of Cancer</i> , 2017, 87, 131-139.	1.3	35
33	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019, 24, e1165-e1171.	1.9	35
34	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019, 39, 4265-4271.	0.5	33
35	Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2014, 15, 411-417.e4.	1.1	32
36	Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. <i>Stem Cells</i> , 2018, 36, 633-640.	1.4	32

#	ARTICLE	IF	CITATIONS
37	Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non- $\small{\text{Small-Cell Lung Cancer}}$. <i>Clinical Lung Cancer</i> , 2014, 15, 418-425.	1.1	31
38	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 31-37.	0.9	31
39	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1369-1378.	0.5	31
40	Lung cancer surgery in oligometastatic patients: outcome and survival. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 1173-1180.	0.6	28
41	Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model. <i>Frontiers in Oncology</i> , 2020, 10, 665.	1.3	27
42	Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. <i>Current Oncology</i> , 2022, 29, 255-266.	0.9	27
43	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2040-2050.	0.5	26
44	Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. <i>Cancers</i> , 2021, 13, 2172.	1.7	25
45	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , 2021, 154, 151-160.	0.9	25
46	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
47	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. <i>British Journal of Cancer</i> , 2018, 118, 38-42.	2.9	23
48	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6361-6376.	1.0	21
49	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR -Mutated Population with Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 801-807.	0.5	21
50	Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey. <i>Frontiers in Oncology</i> , 2020, 10, 584612.	1.3	19
51	The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. <i>Journal of Thoracic Disease</i> , 2017, 9, S1501-S1510.	0.6	18
52	Surgery for small cell lung cancer: When and how. <i>Lung Cancer</i> , 2021, 152, 71-77.	0.9	18
53	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	0.9	17
54	Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. <i>Lung Cancer</i> , 2021, 152, 127-134.	0.9	17

#	ARTICLE	IF	CITATIONS
55	Evaluation of target coverage and margins adequacy during CyberKnife Lung Optimized Treatment. <i>Medical Physics</i> , 2018, 45, 1360-1368.	1.6	16
56	Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?. <i>Clinical Lung Cancer</i> , 2019, 20, 97-106.e1.	1.1	16
57	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. <i>Anticancer Research</i> , 2020, 40, 427-433.	0.5	16
58	A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. <i>Journal of Thoracic Disease</i> , 2018, 10, 3928-3939.	0.6	15
59	Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). <i>OncoTargets and Therapy</i> , 2015, 8, 1997.	1.0	14
60	Outcome of Patients With pN2 "Potentially Resectable" Non-small Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 593-602.	0.4	14
61	Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies. <i>Clinical Lung Cancer</i> , 2017, 18, 489-496.	1.1	14
62	The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. <i>Journal of Clinical Pathology</i> , 2018, 71, 767-773.	1.0	14
63	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 135, 74-77.	0.3	14
64	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020, 12, 2948.	1.7	14
65	A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 676732.	1.3	14
66	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor "Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296.	3.2	14
67	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 135-145.	2.0	12
68	Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (Review). <i>International Journal of Oncology</i> , 2014, 45, 509-515.	1.4	12
69	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1479-1489.	1.4	10
70	30 Immunotherapy in advanced NSCLC "from the "tsunami" of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018, 3, e000298.	2.0	10
71	Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT). <i>Cancers</i> , 2020, 12, 1627.	1.7	10
72	CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2021, 22, 157-159.	5.1	10

#	ARTICLE	IF	CITATIONS
73	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9036-9036.	0.8	10
74	Erlotinib-associated rash in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer treated in the EURTAC trial. Future Oncology, 2015, 11, 421-429.	1.1	9
75	Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?. Journal of Thoracic Disease, 2016, 8, E217-E220.	0.6	9
76	International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-â€Small Cell Lung Cancer: Realities and Hopes. Journal of Thoracic Oncology, 2016, 11, 1153-1169.	0.5	9
77	Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2017, 52, 975-981.	0.6	9
78	<i>ROS1</i> Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm. JCO Precision Oncology, 2017, 1, 1-9.	1.5	9
79	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. Current Clinical Pharmacology, 2018, 13, 76-84.	0.2	9
80	Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice. Expert Review of Respiratory Medicine, 2019, 13, 217-228.	1.0	9
81	Safety Analysis of Salvage Surgery for Advanced Stages or Metastatic Lung Cancers. Thoracic and Cardiovascular Surgeon, 2022, 70, 273-276.	0.4	8
82	Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (<i>ALK</i>) alterations in patients with non-small cell lung cancer. Oncotarget, 2016, 7, 37160-37176.	0.8	8
83	Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. OncoTargets and Therapy, 2014, 7, 697.	1.0	7
84	Afatinib in NSCLC harbouring EGFR mutations. Lancet Oncology, The, 2014, 15, e148-e149.	5.1	7
85	Second-Line Treatment Options in Non-â€Small-Cell-â€Lung Cancer: Report From an-â€International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	1.1	7
86	Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option. Translational Lung Cancer Research, 2018, 7, S100-S102.	1.3	7
87	Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a -no-fly zone-â€TM?. Acta Oncol-â€gica, 2018, 57, 1532-1539.	0.8	7
88	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. Cancers, 2019, 11, 1431.	1.7	7
89	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. Journal of Clinical Medicine, 2019, 8, 112.	1.0	7
90	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1810-1821.	1.3	7

#	ARTICLE	IF	CITATIONS
91	Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets. Chinese Clinical Oncology, 2019, 8, S1-S1.	0.4	7
92	Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer. Clinical Lung Cancer, 2016, 17, e179-e183.	1.1	6
93	<p>Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 125-130.	1.3	6
94	O81–IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1“selected NSCLC. , 2020, , .		6
95	Overcoming resistance to osimertinib in non“small cell lung cancer: Hopes, doubts, and in–between. Cancer, 2020, 126, 2594-2596.	2.0	6
96	What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences. Frontiers in Pharmacology, 2021, 12, 602112.	1.6	6
97	Afatinib in EGFR TKI-Na–ve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in Oncology, 2021, 11, 709877.	1.3	6
98	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8073-8073.	0.8	6
99	Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding. Annals of Translational Medicine, 2019, 7, S80-S80.	0.7	6
100	Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Current Medical Research and Opinion, 2018, 34, 865-871.	0.9	5
101	The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy. Immunotherapy, 2018, 10, 1041-1045.	1.0	5
102	Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study. Jornal Brasileiro De Pneumologia, 2021, 47, e20200584.	0.4	5
103	Afatinib-Related Nonhematologic Adverse Events: Is Common Evaluation Enough for Now?. Journal of Clinical Oncology, 2014, 32, 864-865.	0.8	4
104	Lung Tissue Injury as an Atypical Response to Nivolumab in Non“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1349-1350.	2.5	4
105	Acquired Resistance to Tyrosine Kinase Inhibitors in Non“Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound“Guided Transbronchial Needle Aspiration Samples. Archives of Pathology and Laboratory Medicine, 2018, 142, 465-473.	1.2	4
106	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non“Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa064.	1.4	4
107	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. Expert Review of Molecular Diagnostics, 2021, 21, 757-766.	1.5	4
108	Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Current Oncology, 2021, 28, 3384-3392.	0.9	4

#	ARTICLE	IF	CITATIONS
109	Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.. Journal of Clinical Oncology, 2016, 34, 3067-3067.	0.8	4
110	Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study. Journal of Clinical Medicine, 2021, 10, 3465.	1.0	3
111	First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?. Expert Review of Anticancer Therapy, 2016, 16, 799-801.	1.1	2
112	Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. Expert Review of Clinical Pharmacology, 2016, 9, 1283-1288.	1.3	2
113	Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. Annals of Translational Medicine, 2020, 8, 1111-1111.	0.7	2
114	Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review. Translational Lung Cancer Research, 2021, 10, 3401-3408.	1.3	2
115	Proposals for revisions of the classification of lung cancers with multiple pulmonary sites: the radiologist's, thoracic surgeon's and oncologist's point of view. Journal of Thoracic Disease, 2016, 8, E805-E808.	0.6	1
116	Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints. Translational Lung Cancer Research, 2019, 8, S334-S338.	1.3	1
117	Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterfly. Pulmonology, 2018, 24, 321-322.	1.0	0
118	Reply. Clinical Lung Cancer, 2020, 21, e415-e416.	1.1	0
119	Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. Future Oncology, 2021, 17, 4649-4656.	1.1	0
120	Molecular biomarkers in early-stage lung cancer.. Journal of Clinical Oncology, 2016, 34, e23082-e23082.	0.8	0